2013 Scientific Report

VHIO in 2013: opportunity
towards checkmating cancer

(please browse subchapters below)

Foreword/

Following more than a decade of extraordinary developments in cancer research – from molecular mechanisms to clinical care to new enabling technologies -- we are poised to deliver a much more personalized form of cancer treatment and care to our patients. In 2013, we made tremendous progress in both fine-tuning diagnosis and treatment strategies to the unique molecular make-up of an increasing number of patients, as well as key advancements in our understanding of basic cancer biology and the approval of new tailored therapies. While these efforts span basic, translational and clinical research, they share one unified goal: to outsmart the camouflage and trickery employed by this despicable disease that too often allows it to go undetected, dodge powerful anti-cancer therapeutics, and spread its havoc.

We still have a very long road to travel if we are to conquer cancer. To succeed, we simply must raise the bar and set our ambitions higher than ever. By furthering research, implementing new tools and building integrative platforms, combining our strengths and overcoming current obstacles en force, I believe we can outwit cancer, jump several moves ahead in what can be considered as a biomedical game of chess. This undertaking is undeniably challenging, but, to paraphrase Albert Einstein, in the middle of every challenge lies opportunity.

Considering the developments over the past year, we have good reason to be optimistic.

PDX and optimal preclinical study design

A critical asset in our translational model is our direct access to cancer patients – only possible because of our privileged location within the heart of the Vall d'Hebron University Hospital. This helps us excel in translating research findings for the benefit of patients in record time. It also reduces the risk of costly failures at clinical level, as only a small proportion of initially promising drug candidates ultimately make their way through the clinic and gain approval.

In order to accelerate the development of potent new targeted cancer therapies, our researchers carry out a host of preclinical studies, testing potential agents in combinations as well as rigorously assessing mechanisms of resistance. The goal is to predict success in the clinic and lessen the attrition of new drug entities as they progress through the development pipeline into the clinic. A vital tool in our armory is the development of patient-derived tumor xenograft (PDX) mouse models that faithfully recapitulate cancer. These models help us understand the nuances of tumor development and shape the design of subsequent clinical studies and therapeutic strategies.

Importantly, 2013 marked the launch of a collaboration between VHIO and 14 cancer centers across 9 European countries, called the EuroPDX European Consortium: Translating Knowledge in Oncology. This consortium connects research entities of excellence that are developing clinically relevant PDX cancer models, helping to share key findings on promising therapeutics as well as carry out multi-center preclinical studies.

Teaching anticancer agents new tricks

In our efforts to optimize the appropriate drug at the right dose for each individual patients, we are beginning to reap rewards from clinical studies, building on preclinical studies on novel combination therapies, in larger cohorts of patients. In parallel, we are also seeking out new applications for available chemotherapeutics. The high-throughput screening of previously FDA-approved agents can identify therapeutics that could be rapidly moved to the clinic for new applications.

This so-called 'drug repurposing' could accelerate the development of alternative therapies for cancers that notoriously fail to respond to standard therapies. Furthermore, as we already know a huge amount about any adverse effects, these repurposed compounds are naturally more quickly fit for purpose than their novel, unproven counterparts.

In the Fall of 2013, replacing the European Union Framework Programmes, Horizon 2020 was implemented with the emphasis on frontier and interdisciplinary research. One of the initial topics favors novel studies and clinical approaches supporting the optimization of available therapies, specifically drug repurposing. This represents further opportunity for VHIO to advance current efforts in this arena.

Cancer immunotherapy: a dynamic contender in dismantling cancer's armory

Despite its great promise, the battle to establish immunotherapy as a legitimate cancer therapeutic agent has been messy. There have been several casualties along the way -- failed vaccines, small companies and even careers along a roller coaster of promise and disappointment. Excitement surrounding early phase trial successes has generally evaporated in quick and cruel succession by disappointing and costly failures in late-stage clinical trials.

Thanks to the remarkable dedication of the pioneers and other researchers in this field, we have a new suite of cancer vaccines and promising novel experimental therapies in the pipeline. The new momentum in cancer immunotherapy is incredibly exciting for preclinical and clinical researchers – maybe even game-changing. Apparently the editors of the prestigious journal Science agree: it ranked cancer immunotherapy as number one in its Top 10 Breakthroughs of 2013. We are seeing that immunological strategies really work and should impact the way we treat cancer in the future -- using novel immune agents as mono therapy or in combination, depending on the patient's tumor.

Looking ahead, we eagerly anticipate the application and extension of immunotherapies to more tumor types, as well as combining powerful immunotherapeutic agents with the current cornerstones of cancer -- chemotherapy and radiation. We will also need to better understand the cellular and molecular mechanisms modulating immune response to cancer as well as learn from the outcomes of current and future trials.

At VHIO, we have initiated a campaign to attract principal investigators in cancer immunology and immunotherapy to implement and lead novel research focused on areas such as immuno-oncology, the tumor microenvironment, and the development of immune-based personalized therapeutics. I fully expect that VHIO's multidisciplinary cancer teams will feature new expertise in cancer immune-therapeutics in the year to come.

Oncogenomics data goes 'inter'

Spurred by remarkable developments in DNA sequencing technology that have brought us to the brink of the "$1,000 genome," whole-genome sequencing for precision oncology has been heralded as a trail blazer in cancer research and is already benefiting patients in clinical practice. By sequencing panels of genes or entire genomes in cancer patients, we are now better equipped than ever before to identify specific molecular risk factors and gauge the potential efficacy of specific agents for individual patients.

Despite such progress, we have not yet solved how to harness and store the overwhelming wealth of data generated through oncogenomics. How can we empower researchers and clinicians to exploit this trove of biological knowledge and clinical data? And how can these insights become truly integrated into mainstream healthcare?

To help resolve these challenges, we have been engineering new medically-driven platforms that will ultimately advance precision medicine in oncology by delivering exploitable omics data – genomics, transcriptomics, proteomics and more -- to potential end-users. Our multidisciplinary team of experienced bioinformaticians, experimental and clinical scientists, seeks to design and assess integrative bioinformatics applications, building a platform for the sustainable exploitation of these tools and services for the benefit of patients.

Trial design: efficacy, effectiveness in real time

There is much debate surrounding ways we can improve the design of clinical trials, balancing speed and safety with real-time assessment of data and making fluid adjustments in dosage and treatment as needed. We are excited to drive advances in clinical trial design, to complement the innovation we are seeing at the bench and in our translational research.

During 2013, VHIO has participated in a number of innovative clinical trials in conjunction with centers around the world. While we continue to work closely with industry, we are committed to leading novel academic trials of excellence, supported through public funding.

One such example is the WINTHER (WINTherapeutics) trial, promoted within the scope of the Worldwide Innovative Networking in personalized cancer medicine (WIN) Consortium (supported through a European Union Framework Program 7 grant). This exquisite trial investigates DNA and RNA from dual biopsies of tumor and matched normal tissue for each patient. The gene data are examined by advanced bioinformatics tools to provide a predictive efficacy score for potential drugs for each patient. WINTHER is an exciting response to the call from oncologists for a more aggressive, speedy application of personalized therapy to larger populations of patients.

Another promising partnership is our role in the POSEIDON metastatic breast cancer trial, which investigates a novel PI3K inhibitor. Launched this year (supported by the RATHER and EurocanPlatform consortia in collaboration with Genentech), we are joined by the Netherlands Cancer Institute (NKI, Amsterdam), Cambridge University Hospitals and Cancer Research UK Cambridge Institute. The POSEIDON trial represents Genentech's fist ever investigator-led multi-national study in Europe.

In a similar vein, we are trying to improve our understanding of the distinct molecular subtypes in colorectal cancer, which have different biological hallmarks and -- not surprisingly – varying responses to therapy. The COLTHERES project funded by the European Commission's 7th Framework Programme, is a consortium incorporating European clinical research centers of excellence including VHIO. 2013 has marked notable progress in identifying and validating a number of gene signatures that may be used to establish distinct molecular subgroups of CRC patients. These results have led to the design of various novel clinical trials which are currently enrolling patients with a poor prognosis. This project represents an academically led success story.

Locking the shackles on metastatic spread

For treatment-resistant cancers with a desperately poor prognosis, such as those driven by mutations in the Ras gene (including colon, lung, and pancreatic cancer), we must continue to unmask more specific genomic links as well as study new approaches in treating these patients.

We must also maintain our efforts aimed at checking the mechanisms that cancer cells use to spread and establish metastatic offshoots. Urgent research is still required to counteract and halt tumor cell spread factors with targeted therapies designed with a 'Rolls Royce' sophistication combined with a finale roar of a Ferrari! Many studies have shown that the shotgun approach often leads to regression of disease, with a more fast and furious return than the original cancer.

At the research level, we need to get much smarter at tracking down circulating tumor cells that drive metastasis. The early detection of these sinister cells is imperative. Sophisticated nanotechnologies are already promising the quantification of biomarkers expressed on cancer cells which will help us to distinguish between the devil cancer cells and the deep-blue sea of healthy cells.

We are now upon the eve of moving into our new home, the CELLEX building. By bringing all our preclinical, translational and clinical research teams under the same roof, for an even faster exchange of ideas and results, we will undoubtedly be better equipped to spur this vital future research into paralyzing metastatic activity that currently threatens the lives of countless cancer patients every year. One patient is one too many.

At VHIO, we determinedly translate current challenges in winning the war on cancer into opportunities towards victory.


Josep Tabernero
Director. The Vall d'Hebron Institute of Oncology (VHIO)



Who we are and what we do/

VHIO’s Organigram 2013

In order to translate research findings for the benefit of patients in record time, VHIO adopts a purely translational, multidisciplinary research model. Organized into four main programs – Preclinical, Translational, Clinical, and Core Technologies, our research focuses on understanding the fundamental biology of human cancer, from cellular and molecular biology and genetics through to therapeutics.

Its optimal organizational structure allows VHIO to relentlessly tackle the many unresolved questions in ultimately outsmarting the multifaceted, heterogeneous and complex disease that is cancer:



VHIO's direct access to cancer patients: a critical asset in VHIO's purely translational research model

At the preclinical, translational and clinical research levels VHIO continues to drive key advancements in cancer science and medicine (click here for VHIO’s full list of publications in 2013, and an overview of Scientific Productivity as well as selected articles). Our research endeavors largely benefit from VHIO's privileged location within the heart of the Vall d'Hebron University Hospital, affording direct access to patients as well as the entire spectrum on oncology patients who care for them. Organized into multidisciplinary integrated teams, our researchers can closely collaborate and interact with Vall d'Hebron physician-scientists. Translational science and clinical research are therefore tightly connected, accelerating the bench-bedside-bed cycle of knowledge.

The Vall d'Hebron University Hospital: the largest hospital complex in Catalonia and one of the largest in Spain.



A little of how we did it in 2013/

Oncogenomics at VHIO: accelerating discovery translating to cures

At the heart of VHIO's research activities lies our suite of cutting-edge core technology platforms which enable us to apply next-generation whole-genome sequencing for precision oncology. By sequencing panels of genes or entire genomes in cancer patients, we are now better equipped than ever before to identify specific molecular risk factors and gauge the potential efficacy of specific agents for individual patients. In parallel, these technologies immensely benefit and accelerate the research efforts of our preclinical, translational and clinical scientists, including the identification of mechanisms of resistance to targeted therapies, the study of clonal populations, as well as defining novel therapeutic opportunities based on mutation profiles.

Our Cancer Genomics Group, equipped with a genotyping platform (MassARRAY sequenom) and two NextGen sequencers; MiSeq and HiSeq2500, Illumina, provides a pre-screening program of mutations in patients who are candidates for our portfolio of phase I clinical trials (please refer to our Research Unit for Molecular Therapy of Cancer (UITM) - ”la Caixa”).

The molecular profile of each patient indicates his/her suitability for inclusion in a given clinical trial aimed at testing the usefulness of novel targeted therapies, such as PIK3CA, AKT1, BRAF or MEK inhibitors. These endeavors are not only revolutionizing tumor classification but also increasingly impacting on how cancer treatment decisions are made.

As a reflection of our commitment to excellence, one key development in 2013 has been obtaining ISO 15189:2007certification for both our Cancer Genomics and Molecular Oncology Groups. VHIO has consequently become one of the first research institutes in Spain to meet this standard, demonstrating its technical competencies, level of quality, standardization, validation of processes and staff training. Such accreditation is highly valued by the companies and institutions that seek to collaborate with us – in recognition that quality is key to competitiveness.

Incorporated only last year, our Translational Genomics Group has successfully implemented the technology, equipment and protocols to facilitate gene expression data in both the nCounter Nanostring and RNAseq platforms. Concerning the former, incidentally ranking 4th in The Scientist's Top 10 Innovations for 2013, the group is one of the first to provide this commercial assay in Europe. Using this assay, the group has this year shown that HER2+ breast cancer can be classified into four different subtypes, one of which demonstrates both a greater response to and increased benefit from chemotherapy and anti-HER2 therapy. Such newly, refined classification of different tumor subtypes will ultimately facilitate more effective treatment tailored to a specific tumor as well as advance targeted therapy against HER2+ breast cancer.

By bringing more detailed prognostics directly to the clinical setting, and further developing and validating the next generation of tests, VHIO will significantly contribute to better guided treatment decisions as well as improved outcomes for patients, real time.



Clinical Trials at VHIO: driving drug development and targeted therapies against cancer

VHIO has increasingly established itself as a leading reference in drug discovery from concept to clinic:



Research Unit for Molecular Therapies of Cancer (UITM) "la Caixa": fighting cancer's biology, one patient at a time


Directed by Josep Tabernero, under the clinical coordination of Jordi Rodón, the Research Unit for Molecular Therapy of Cancer (UITM) - "la Caixa" was inaugurated in June 2010 thanks to the support received from the Welfare Projects Division of "la Caixa" Foundation in order to develop new drugs based on the molecular profile of each tumor and optimize treatment regimes using combinations of new drugs with existing ones.

This Unit, a pioneering project at national level, also benefits from the same privileged environment enjoyed by VHIO; located in the patient care environment of the Vall d'Hebron University Hospital and set within the research context. This excellent bridging and tight connectivity between health care and research enables us to establish new treatment models for patients with highly selective drugs, expanding the knowledge of tumor diseases and how to treat them in an individualized way - getting the right drug to the right patient at the right time.

In the space of just three years since it was inaugurated, among many other successes, through the research carried out by VHIO's Early Clinical Drug Development Group the Unit has firmly established itself as a leading reference with the most expertise in various areas of drug development including P13K/akt/ mTOR inhibitors, FGFR inhibitors or drugs targeting developmental pathways such as TGF beta, SHH, WNT, and NOTCH.

Thanks to the Unit's outstanding facilities coupled with the excellent multidisciplinary clinical teams of professionals, 2013 witnessed a further increase in phase I trials numbering at 75 and enrolling a total of 345 patients.

While we continue to expand our portfolio of phase I trials, adding new targeted therapies against novel, promising targeted therapies and best-in-class therapies, the technology platforms provided by VHIO's Cancer Genomics and Translational Cancer Genomics, such as the MiSeq sequencing system and nCounter Nanostring platform respectively, will drive faster and more precise mutational analysis of tumor-suppressor genes as well as translocations and gene amplifications.

It's not only about speed and precision. Importantly this year, both our Cancer Genomics, and Molecular Oncology Groups received ISO accreditation – further endorsing the quality and excellence epitomizing our activities.



Clinical Trials Office


Established in 1997, the Clinical Trials Office at the Vall d'Hebron University Hospital coordinates studies from Phase I to Phase III and is organized in three separate teams: Phase I, Breast Cancer, and Phase II - III. Thanks to the dedication and drive of more than 30 professionals including study coordinators, data managers and administrative staff, this Office reports exciting growth in both the number of patients enrolled in trials as well as trials conducted each year. 2013 continues the trend - totaling 232 Phase I-II-III trials with 843 patients recruited.


To consult the full list of highlights and a summary of activity in 2013 click here.



VHIO's participation in International Consortia of excellence


We can only hope to accelerate discovery and thus improved cancer treatment and care by combining our strengths and overcoming current obstacles in collaboration. 2013 has marked the launch of several unique, cross-border opportunities which will ultimately avoid duplication of research efforts but also spur advancements making personalized medicine more precise and accessible for an increasing number of patients:

The EuroPDX Consortium – Translating Knowledge in Oncology (see the Foreword to this report: PDX and optimal preclinical study design), was launched in 2013 with the common goal of creating a network of clinically relevant models of human cancer, and in particular patient-derived xenograft (PDX) models. Connecting 14 cancer centers across 9 European countries that are developing PDX cancer models, this initiative will promote the sharing and exchange of findings on promising therapeutics as well as lead multi-center preclinical studies.

EuroPDX will strive to reduce the duplication of efforts in oncology drug development and ultimately improve the quality of life and overall survival of cancer patients.

Announced in 2013, The MErCuRIC Consortium, funded by the European Commission's 7th Framework Programme of Research and Development, incorporates 13 partners in eight different European countries to lead and pioneer a multicentre phase Ib/II clinical trial.

This study will assess a novel therapeutic strategy aimed at combating metastasis, improving survival and developing new approaches to treat patients with colorectal cancer. http://mercuric.eu.

Launched in 2011 (VHIO joined in 2013), supported by the IMI Innovative Medicines Initiative – a Joint Undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA), OncoTrack, Methods for systematic next generation oncology biomarker development, is an international consortium of over 80 scientists and constitutes one of Europe's largest collaborative academic-industry efforts aimed at developing and assessing novel approaches for the identification of new markers for colon cancer.

Incorporating a network of 27 research entities spanning 10 countries, SPECTAcolor - Screening Platform for Efficient Clinical Trials Access in Colorectal cancer, is an initiative within the framework of the research program of the EORTC, supported by Alliance Boots. Launched this year, 2013, this is the first prospective fully annotated tumor samples Biobank and Biomarker analysis platform for genetic profiling of patients suffering from advanced colorectal cancer. http://spectacolor.eortc.org.

In addition to these new opportunities embraced in 2013, VHIO continues to participate in on-going Consortia of excellence including: RATHER – Rational Therapy for Breast Cancer, EurocanPlatform, COLTHERES – Colon Therapy Research Consortium, and WIN – Worldwide Innovative Networking in personalized cancer medicine. Just some of the exciting developments resulting from these four collaborations in 2013 have been suitably highlighted in the Foreword to this Scientific Report (see Foreword to this report: Trial design: efficacy, effectiveness in real time).

(please click here for the full list of Consortia and respective project overviews).

Other collaboration:

2013 marked the launch of the CIBOT Consorcio de Investigación Biomédica y Oncología Traslacional (Consortium for Biomedical and Translational Research in Oncology), a new scientific program in collaboration with Novartis. This initiative will define and develop research aimed at: determining the etiopathogenic mechanisms of cancer as well as developing novel or more efficient diagnostic and therapeutic tools; investigating the therapeutic potential of new antineoplastic agents; and applying cutting-edge technologies and latest data to advance cancer research. Specific areas of interest include the effects of HER-2 amplification pattern and prior Herceptin/TDM-1 therapy on HER-2 expression, the therapeutic inhibition of the oncogenic Wnt/beta-catenin pathway, and targeting wild type c-KIT combination with PI3K pathway inhibition in basallike PDXs. www.novartis.com

The OCTC - Oncology Clinical and Translational Consortium, a collaborative scientific research network comprised of six renowned comprehensive cancer centers, was launched by GSK at the end of 2013. While GSK will gain OCTC's expertise in preclinical, translational and clinical development of novel anticancer therapeutics, the participating centers will have access to studies with GSK's early stage oncology pipeline and opportunities to accelerate and advance the next generation of novel oncology therapeutics. www.gsk.com.



Cancer research at VHIO: dismantling cancer's armory

Leading scientific discovery against cancer, in 2013 our preclinical, translational and clinical researchers published 151 scientific articles as corresponding/senior or co-authors, with a Median Impact Factor (MIF) of 9.27. These figures reflect an increase in scientific productivity -- witnessed year in, year out, a maintained MIF score, as well as the importance of VHIO's research and contribution to the field.

(Click here for the complete list of articles published by VHIO researchers and physician-scientists in 2013. To view this year's selection of just some of the most relevant articles by VHIO Faculty published in 2013).



The CELLEX building: connecting and expanding VHIO's multidisciplinary research teams – the drivers behind more effective, targeted therapies against cancer



2013 has witnessed the completion of the construction of VHIO's new home: the CELLEX building. In the space of just one year since we compiled our 2012 Scientific Report, we are now in the throes of planning towards equipping its interior.

Importantly, to further develop our research of excellence involving patient-derived tumor xenograft (PDX) mouse models that faithfully recapitulate cancer (please see the Foreword to this report: PDX and optimal preclinical study design), we have been finalizing the plans for our new Animal Facility. With a capacity of over 5000 cages, adopting a state-of-the-art recycling system, this facility will benefit the endeavors of VHIO scientists and our colleagues at the Vall d'Hebron Research Institute (VHIR), as well as those belonging to other CERCA-accredited research centers (CERCA - Institute of Research Centers of Catalunya), such as the Institute of Photonic Sciences (ICFO).

Marking an exciting new era towards precision oncology, we are upon the eve of the final completion of the CELLEX building. This will not only provide VHIO with the space it desperately requires to be able to expand its programs and activities, but will also bring all our research teams under the same roof, for an even faster exchange and application of data -- the key to better serving cancer science and medicine, and most importantly of all, ultimately improve the lives of those touched and affected by cancer.



With the invaluable support:





VHIO-organized events: debate and exchange of the highest degree

In 2013 VHIO opened its doors to participants at the following events:



VHIO Meet the Editors

Our 2013 annual series of VHIO Meet the Editors prestigious talks provided oncology professionals of research institutes of excellence in Barcelona with unique opportunity to learn more about scientific publishing and cancer research and put questions and comments to the editors directly during the Q & A with the audience. They also continued to provide valuable opportunity to get to know the editors of the highest impact factor journals personally:

VHIO's Meet the Editors in 2013:


Speaker: Li-Kuo Su, Editor-in-Chief
Talk: Cancer Cell and the Cancer Research Community
Date: 14 January 2013


Speaker: David Collingridge, Editor-in-Chief
Talk: Insights on editorial decision-making and peer review
Date: 26 July 2013

As this Scientific Report goes to print, we are pleased to announce the following dates in the diary for 2014:



Speaker: Judy Quong, Executive Editor of Cancer Discovery
Talk: Cancer Discovery: Looking Back, Moving Forward
Date: 24 February 2013

Speaker: Jean-Charles Soria, Editor-in-Chief
Talk: Annals of Oncology
Date: 08 September 2014

Speaker: Alexander M. M. Eggermont, Editor-in-Chief, EJC
Date: 15 December 2014



The 17th Fritz Bender Foundation International Symposium: Progress towards Individualized Cancer Treatments, 07-09 November, Barcelona (Spain) – co-organized and hosted by VHIO



As we advanced in our 2012 VHIO Scientific Report, in collaboration with the Fritz Bender Foundation, VHIO coorganized and hosted the 17th Fritz Bender Foundation International Symposium on Progress towards Individualized Cancer Treatments, 07-09 November 2013, here at the Vall d'Hebron University Hospital campus.

Established by the Fritz Bender Foundation, and expertly engineered by Kurt S. Zaenker (the Fritz Bender Foundation, and University of Witten/Herdecke, Germany), and Enrico Mihich (the Dana Farber Cancer Institute, Boston, USA), the main aim of these symposia is to provide a unique platform for up and coming young researchers and physician-scientists to interact, exchange, and debate with current thought-leaders within the oncology field.

Secondly, these meetings seek to promote the latest advances within the field at international level in order to also impact at local level. This is achieved by identifying the most suitable research institute as co-organizer to host in the respective country selected for each symposium.

For 2013, VHIO was honored to host and co-organize the 17th in the symposium series, with the support of an educational grant received through the "la Caixa" Foundation:

Incorporating an outstanding panel of internationally renowned speakers, and attracting some 250 participants, the symposium ran for two and a half days organized into five main sessions: 1) Genetic Profiling of Patients, 2) Tumor Characterization, 3) Tumor-Host Relationships, 4) Therapeutic Targets I, and 5) Therapeutic Targets II.

In addition to the main scientific program, which delivered on addressing some of the many remaining questions in our efforts to change the face of cancer through precision cancer treatment and care, we all discovered yet more relevant and recent advances within the oncology field throughout the poster sessions. In recognition of these contributions, in collaboration with VHIO, both Nature Reviews Cancer and Nature Reviews Clinical Oncology each sponsored a poster prize awarded to the two top posters.

The 17th Fritz Bender Foundation International Symposium: Progress towards Individualized Cancer Treatments, 07-09 November, Barcelona (Spain) – co-organized and hosted by VHIO.

The 2013 edition of these Symposia both matched and celebrated the successes of past Fritz Bender Foundation International meetings, elegantly captured in a special meeting report published in Molecular Oncology, Volume 8, Issue 1, February 2014, Pages 1–8, News and Views, Towards individualized cancer therapy: Challenges and prospects, authored by Ezzie Hutchinson.

The 17th Fritz Bender Foundation International Symposium: Progress towards Individualized Cancer Treatments, 07-09 November, Barcelona (Spain) – co-organized and hosted by VHIO.



VHIO ad-hoc Courses, Workshops & Observerships



Based on specific research lines and areas that have successfully established VHIO as a leading international reference, we share our expertise, learn from eminent guest speakers, discuss and debate our latest findings through the organization of VHIO ad-hoc courses and workshops as well as VHIO Faculty attendance at International Cancer Conferences.



Contact: +34 93 489 30 21 Email: info@vhio.net    |    © Vall d'Hebron Institute of Oncology (VHIO)    |    Photography: Katherin Wermke